%0 Journal Article
%T Resmetirom for treatment of MASH.
%A Sookoian S
%A Pirola CJ
%J Cell
%V 187
%N 12
%D 2024 Jun 6
%M 38848671
%F 66.85
%R 10.1016/j.cell.2024.05.009
%X Resmetirom is an oral selective THR-β agonist conditionally approved for the treatment of patients with noncirrhotic MASH with moderate to advanced fibrosis. Resmetirom restores mitochondrial and hepatic metabolic function; reduces atherogenic lipids; improves hepatic steatosis, inflammation, and fibrosis; and has no significant effect on THR-α. To view this Bench to Bedside, open or download the PDF.